Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;19(5):614-8.
doi: 10.1038/nm.3174. Epub 2013 Apr 14.

Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions

Affiliations

Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions

Felipe De Sousa E Melo et al. Nat Med. 2013 May.

Abstract

Colon cancer is a clinically diverse disease. This heterogeneity makes it difficult to determine which patients will benefit most from adjuvant therapy and impedes the development of new targeted agents. More insight into the biological diversity of colon cancers, especially in relation to clinical features, is therefore needed. We demonstrate, using an unsupervised classification strategy involving over 1,100 individuals with colon cancer, that three main molecularly distinct subtypes can be recognized. Two subtypes have been previously identified and are well characterized (chromosomal-instable and microsatellite-instable cancers). The third subtype is largely microsatellite stable and contains relatively more CpG island methylator phenotype-positive carcinomas but cannot be identified on the basis of characteristic mutations. We provide evidence that this subtype relates to sessile-serrated adenomas, which show highly similar gene expression profiles, including upregulation of genes involved in matrix remodeling and epithelial-mesenchymal transition. The identification of this subtype is crucial, as it has a very unfavorable prognosis and, moreover, is refractory to epidermal growth factor receptor-targeted therapy.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Gut. 2004 Aug;53(8):1137-44 - PubMed
    1. BMC Med Genomics. 2012 Dec 31;5:66 - PubMed
    1. J Clin Oncol. 2011 Jan 1;29(1):17-24 - PubMed
    1. Br J Cancer. 2012 Jan 3;106(1):126-32 - PubMed
    1. Nat Med. 2007 Sep;13(9):1070-7 - PubMed

Publication types

Associated data